AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
The FDA’s focus on speeding up new clinical trials has spurred the opening of a new office within the Center for Drug Evaluation and Research, the agency said. The acting director of ...
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...
Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results